Eikon pulls in $351M as lead drugs begins Phase III journey

Eikon Therapeutics Secures $350.7 Million Series D to Advance Cancer Drug Pipeline Eikon Therapeutics, a pivotal-stage biotechnology company, has raised $350.7 million in a Series D financing round to support its clinical-stage programs and future pipeline development147. This significant funding brings Eikon’s total capital raised since its founding in 2019 to over $1.1 billion17. ## […]

Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

Patient-centered epilepsy care, Holistic epilepsy management, Quality of life in epilepsy, Empowering epilepsy patients, Multidisciplinary epilepsy treatment, Epilepsy patient experiences, Comprehensive epilepsy support